Roche Hit By Surprising Tecentriq Miss In TNBC
Has Improved Survival With Nab-Paclitaxel But Not With Paclitaxel
Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.
